Recursion Pharmaceuticals, Inc. (RXRX) stock forecast and price target
Price $3.19 · data as of November 13, 2026
12-month price target
Average target$7.32
Upside / downside+129.7%
Analysts6
ConsensusBuy
Low $4.00Average $7.32High $10.00
Gold marker: average target · white marker: today’s price ($3.19)
Analyst ratings
Strong buy 2Buy 1Hold 4Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.88 | +38.8% | $40M |
| Next fiscal year ends December 31, 2027 | $-0.81 | +8.2% | $44M |
| Next quarter ends December 31, 2026 | $-0.21 | +0.8% | $8M |
| Quarter after ends March 31, 2027 | $-0.19 | +12.5% | $6M |
Consensus of the analysts covering Recursion Pharmaceuticals, updated daily. In the last 30 days 3 estimates were raised and 1 lowered.
Frequently asked questions
What is the Recursion Pharmaceuticals stock price target?
The average 12-month target from 6 analysts is $7.32, 129.7% above the current price of $3.19 Targets range from $4.00 to $10.00.
Is Recursion Pharmaceuticals a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 1 buy, 4 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Recursion Pharmaceuticals expected to earn?
Analysts expect EPS of $-0.88 for the fiscal year ending December 31, 2026 and $-0.81 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.